Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 6
1976 1
1977 5
1978 4
1979 8
1980 23
1981 47
1982 43
1983 61
1984 64
1985 74
1986 66
1987 58
1988 89
1989 99
1990 61
1991 85
1992 104
1993 125
1994 150
1995 122
1996 150
1997 158
1998 185
1999 181
2000 208
2001 211
2002 217
2003 262
2004 294
2005 345
2006 334
2007 352
2008 381
2009 444
2010 431
2011 475
2012 511
2013 551
2014 558
2015 625
2016 366
2017 298
2018 400
2019 396
2020 433
2021 496
2022 447
2023 384
2024 172

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,412 results

Results by year

Filters applied: . Clear all
Page 1
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Kumagai S, et al. Among authors: sakamoto n. Cancer Cell. 2022 Feb 14;40(2):201-218.e9. doi: 10.1016/j.ccell.2022.01.001. Epub 2022 Jan 28. Cancer Cell. 2022. PMID: 35090594 Free article.
The balance of programmed death-1 (PD-1)-expressing CD8(+) T cells and regulatory T (Treg) cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 blockade therapy through the competition of their reactivation. ...Here, we show that Treg c …
The balance of programmed death-1 (PD-1)-expressing CD8(+) T cells and regulatory T (Treg) cells in the tumor microenvironment …
Dectin-1 signaling on colonic gammadelta T cells promotes psychosocial stress responses.
Zhu X, Sakamoto S, Ishii C, Smith MD, Ito K, Obayashi M, Unger L, Hasegawa Y, Kurokawa S, Kishimoto T, Li H, Hatano S, Wang TH, Yoshikai Y, Kano SI, Fukuda S, Sanada K, Calabresi PA, Kamiya A. Zhu X, et al. Among authors: sakamoto s. Nat Immunol. 2023 Apr;24(4):625-636. doi: 10.1038/s41590-023-01447-8. Epub 2023 Mar 20. Nat Immunol. 2023. PMID: 36941398 Free PMC article.
We show that reduction in specific Lactobacillus species, which are involved in T cell differentiation to protect the host immune system, contributes to stress-induced social-avoidance behavior, consistent with our observations in patients with depression. Stress-susceptib …
We show that reduction in specific Lactobacillus species, which are involved in T cell differentiation to protect the host immune sys …
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y, Shiraiwa H, Azuma Y, Tsunenari T, Kayukawa Y, Sonobe Y, Ono N, Sakata K, Fujii T, Miyazaki Y, Noguchi M, Endo M, Harada A, Frings W, Fujii E, Nanba E, Narita A, Sakamoto A, Wakabayashi T, Konishi H, Segawa H, Igawa T, Tsushima T, Mutoh H, Nishito Y, Takahashi M, Stewart L, ElGabry E, Kawabe Y, Ishigai M, Chiba S, Aoki M, Hattori K, Nezu J. Ishiguro T, et al. Among authors: sakamoto a. Sci Transl Med. 2017 Oct 4;9(410):eaal4291. doi: 10.1126/scitranslmed.aal4291. Sci Transl Med. 2017. PMID: 28978751
Cancer care is being revolutionized by immunotherapies such as immune checkpoint inhibitors, engineered T cell transfer, and cell vaccines. The bispecific T cell-redirecting antibody (TRAB) is one such promising immunotherapy, which can redirect T cells to tu …
Cancer care is being revolutionized by immunotherapies such as immune checkpoint inhibitors, engineered T cell transfer, and cell vac …
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G, Garrigan E, Xu P, Huang J, Salzer B, Delaidelli A, Raman S, Cui H, Martinez B, Bornheimer SJ, Sahaf B, Alag A, Fetahu IS, Hasselblatt M, Parker KR, Anbunathan H, Hwang J, Huang M, Sakamoto K, Lacayo NJ, Klysz DD, Theruvath J, Vilches-Moure JG, Satpathy AT, Chang HY, Lehner M, Taschner-Mandl S, Julien JP, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL. Heitzeneder S, et al. Among authors: sakamoto k. Cancer Cell. 2022 Jan 10;40(1):53-69.e9. doi: 10.1016/j.ccell.2021.12.005. Epub 2021 Dec 30. Cancer Cell. 2022. PMID: 34971569 Free PMC article.
Pediatric cancers often mimic fetal tissues and express proteins normally silenced postnatally that could serve as immune targets. We developed T cells expressing chimeric antigen receptors (CARs) targeting glypican-2 (GPC2), a fetal antigen expressed on neuroblastoma (NB) …
Pediatric cancers often mimic fetal tissues and express proteins normally silenced postnatally that could serve as immune targets. We develo …
Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution.
Suma S, Suehara Y, Fujisawa M, Abe Y, Hattori K, Makishima K, Sakamoto T, Sawa A, Bando H, Kaji D, Sugio T, Kato K, Akashi K, Matsue K, Carreras J, Nakamura N, Suzuki A, Suzuki Y, Ito K, Shiiba H, Chiba S, Sakata-Yanagimoto M. Suma S, et al. Among authors: sakamoto t. Leukemia. 2024 Feb;38(2):340-350. doi: 10.1038/s41375-023-02093-7. Epub 2023 Nov 27. Leukemia. 2024. PMID: 38012392 Free PMC article.
T follicular helper (T(FH)) cell lymphomas (TFHLs) are characterized by T(FH)-like properties and accompanied by substantial immune-cell infiltration into tumor tissues. ...Notably, we found a significant increase in exhausted CD8(+) T cells with oligo
T follicular helper (T(FH)) cell lymphomas (TFHLs) are characterized by T(FH)-like properties and accompanied by substa
Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells.
Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, Sakamoto S, Watanabe A, Ohara K, Wang B, Xu H, Minagawa A, Hotta A, Woltjen K, Uemura Y, Kodama Y, Seno H, Nakatsura T, Tamada K, Kaneko S. Ueda T, et al. Among authors: sakamoto s. Nat Biomed Eng. 2023 Jan;7(1):24-37. doi: 10.1038/s41551-022-00969-0. Epub 2022 Dec 12. Nat Biomed Eng. 2023. PMID: 36509913 Free PMC article.
The effectiveness of chimaeric antigen receptor (CAR) T-cell immunotherapies against solid tumours relies on the accumulation, proliferation and persistency of T cells at the tumour site. ...In multiple tumour-bearing animal models, the engineered hiPSC-derived CAR …
The effectiveness of chimaeric antigen receptor (CAR) T-cell immunotherapies against solid tumours relies on the accumulation, prolif …
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment.
Leca J, Lemonnier F, Meydan C, Foox J, El Ghamrasni S, Mboumba DL, Duncan GS, Fortin J, Sakamoto T, Tobin C, Hodgson K, Haight J, Smith LK, Elia AJ, Butler D, Berger T, de Leval L, Mason CE, Melnick A, Gaulard P, Mak TW. Leca J, et al. Among authors: sakamoto t. Cancer Cell. 2023 Feb 13;41(2):323-339.e10. doi: 10.1016/j.ccell.2023.01.003. Epub 2023 Feb 2. Cancer Cell. 2023. PMID: 36736318 Free article.
Angioimmunoblastic T cell lymphoma (AITL) is a peripheral T cell lymphoma that originates from T follicular helper (Tfh) cells and exhibits a prominent tumor microenvironment (TME). ...
Angioimmunoblastic T cell lymphoma (AITL) is a peripheral T cell lymphoma that originates from T follicular helper (Tfh …
Expansion of CD4+ cytotoxic T lymphocytes with specific gene expression patterns may contribute to suppression of tumor immunity in oral squamous cell carcinoma: single-cell analysis and in vitro experiments.
Chen H, Sameshima J, Yokomizo S, Sueyoshi T, Nagano H, Miyahara Y, Sakamoto T, Fujii S, Kiyoshima T, Guy T, Nakamura S, Moriyama M, Kaneko N, Kawano S. Chen H, et al. Among authors: sakamoto t. Front Immunol. 2023 Nov 23;14:1305783. doi: 10.3389/fimmu.2023.1305783. eCollection 2023. Front Immunol. 2023. PMID: 38077321 Free PMC article.
METHODS: In this study, we examined immune responses and effector functions of CD4(+) T cells, CD8(+) T cells and B cells infiltrating in OSCC lesions using single-cell RNA sequencing analysis, T cell receptor (TCR) and B cell receptor (BCR) repertoire sequen …
METHODS: In this study, we examined immune responses and effector functions of CD4(+) T cells, CD8(+) T cells and B cells infi …
cis interaction of CD153 with TCR/CD3 is crucial for the pathogenic activation of senescence-associated T cells.
Fukushima Y, Sakamoto K, Matsuda M, Yoshikai Y, Yagita H, Kitamura D, Chihara M, Minato N, Hattori M. Fukushima Y, et al. Among authors: sakamoto k. Cell Rep. 2022 Sep 20;40(12):111373. doi: 10.1016/j.celrep.2022.111373. Cell Rep. 2022. PMID: 36130493 Free article.
With age, senescence-associated (SA) CD4(+) T cells that are refractory to T cell receptor (TCR) stimulation are increased along with spontaneous germinal center (Spt-GC) development prone to autoantibody production. ...Administration of an anti-CD153 antibody block …
With age, senescence-associated (SA) CD4(+) T cells that are refractory to T cell receptor (TCR) stimulation are increased alo …
[Adoptive cell therapy for solid tumors].
Sakamoto K, Yagyu S. Sakamoto K, et al. Rinsho Ketsueki. 2024;65(7):652-661. doi: 10.11406/rinketsu.65.652. Rinsho Ketsueki. 2024. PMID: 39098016 Review. Japanese.
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment paradigm for refractory/relapsed (R/R) hematologic malignancies, with six products approved for B-cell tumors and multiple myeloma as of the end of 2023. However, adoptive cell therapy (ACT) fo …
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment paradigm for refractory/relapsed (R/R) hematologic ma …
10,412 results
You have reached the last available page of results. Please see the User Guide for more information.